MaxCyte Latest News FEATURED NEWS MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs Load More Receive upcoming events, new resources and more in your inbox Email Address(Required) April 2, 2024 MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs March 18, 2024 MaxCyte Minutes Newsletter – Q1 2024 Welcome to the latest edition of the MaxCyte Minutes newsletter! We feature news, events, and technical content to support your next project. We aim to empower you to expedite your research journey from concept to clinic and commercialization. MaxCyte Puts A Focus On: Maher Masoud, CEO Maher was named President and Chief Executive Officer of MaxCyte in January of 2024. He brings more than 25 years of experience in the biopharmaceutical industry, including 17 years as an attorney and general counsel, to his new role at MaxCyte. Load More News